Litcius/Paper detail

Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Bart J. Biemond, Anıl Tombak, Yurdanur Kılınç, Murtadha Al‐Khabori, Miguel R. Abboud, Mohammed Nafea, Adlette Inati, Yasser Wali, Jens Kristensen, Jan Kowalski, Ellen Donnelly, John Öhd, Erfan Nur, Anita W. Rijneveld, Alibülent Antmen, Marvin Reid, Gabriel Ukala, Lisa Kirven-Dawes, Curis Yeates, Hugh Wong, Abdulrahman Al Sultan

2021The Lancet Haematology38 citationsDOI

Topics & Concepts

MedicinePlaceboVaso-occlusive crisisPopulationSickle cell anemiaClinical endpointClinical trialAcute chest syndromeInternal medicinePediatricsSurgeryDiseaseEnvironmental healthPathologyAlternative medicineHemoglobinopathies and Related DisordersHeparin-Induced Thrombocytopenia and ThrombosisVenous Thromboembolism Diagnosis and Management
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Litcius